Toshihiko Doi

Gastrointestinal oncologist and early-phase trialist who directs Japan's National Cancer Center Hospital East.

Toshihiko Doi is Director of National Cancer Center Hospital East in Kashiwa, Japan, one of the country's leading cancer hospitals and a major site for first-in-human oncology trials. His research focuses on gastrointestinal cancers and early clinical development, including pivotal work on trastuzumab deruxtecan and trifluridine/tipiracil in gastric cancer. He has led numerous phase 1 to 3 studies of novel anticancer agents in Asian populations.

Role

Director

Institution

National Cancer Center Hospital East

Specialisms

Gastrointestinal oncologyEarly-phase drug developmentGastric cancer

Profiles

Papers

3top

Title	Journal	Year
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial	Lancet Oncology	2018
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study	Lancet Oncology	2019
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study	Lancet Oncology	2017